Send to:

Choose Destination
See comment in PubMed Commons below
J Pharmacol Toxicol Methods. 2014 Jan-Feb;69(1):61-101. doi: 10.1016/j.vascn.2013.05.004. Epub 2013 May 17.

Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortium.

Author information

  • 1Charles River Laboratories, 6995 Longley Lane, Reno, NV 89511, USA. Electronic address:
  • 2Statistik Georg Ferber GmbH, Cagliostrostrasse 14, 4125 Riehen, Switzerland. Electronic address:
  • 3Centre de Recherches Biologiques, CERB, Chemin de Montifault, 18800 Baugy, France. Electronic address:
  • 4Bristol-Myers Squibb, Discovery Toxicology, Route 206 and Provinceline Road, Princeton, NJ 08543, USA. Electronic address:
  • 5Chugai Pharmaceutical Co., Ltd., Research Division, 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan. Electronic address:
  • 6F. Hoffmann-La Roche, Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland. Electronic address:
  • 7MPI Research, Inc., 54943 North Main Street, Mattawan, MI 49071, USA. Electronic address:
  • 8F. Hoffmann-La Roche, Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland. Electronic address:
  • 9Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA. Electronic address:



In vivo models have been required to demonstrate relative cardiac safety, but model sensitivity has not been systematically investigated. Cross-species and human translation of repolarization delay, assessed as QT/QTc prolongation, has not been compared employing common methodologies across multiple species and sites. Therefore, the accurate translation of repolarization results within and between preclinical species, and to man, remains problematic.


Six pharmaceutical companies entered into an informal consortium designed to collect high-resolution telemetered data in multiple species (dog; n=34, cynomolgus; n=37, minipig; n=12, marmoset; n=14, guinea pig; n=5, and man; n=57). All animals received vehicle and varying doses of moxifloxacin (3-100 mg/kg, p.o.) with telemetered ECGs (≥500 Hz) obtained for 20-24h post-dose. Individual probabilistic QT-RR relationships were derived for each subject. The rate-correction efficacies of the individual (QTca) and generic correction formulae (Bazett, Fridericia, and Van de Water) were objectively assessed as the mean squared slopes of the QTc-RR relationships. Normalized moxifloxacin QTca responses (Veh Δ%/μM) were derived for 1h centered on the moxifloxacin Tmax.


All QT-RR ranges demonstrated probabilistic uncertainty; slopes varied distinctly by species where dog and human exhibited the lowest QT rate-dependence, which was much steeper in the cynomolgus and guinea pig. Incorporating probabilistic uncertainty, the normalized QTca-moxifloxacin responses were similarly conserved across all species, including man.


The current results provide the first unambiguous evidence that all preclinical in vivo repolarization assays, when accurately modeled and evaluated, yield results that are consistent with the conservation of moxifloxacin-induced QT prolongation across all common preclinical species. Furthermore, these outcomes are directly transferable across all species including man. The consortium results indicate that the implementation of standardized QTc data presentation, QTc reference cycle lengths, and rate-correction coefficients can markedly improve the concordance of preclinical and clinical outcomes in most preclinical species.

Copyright © 2013 Elsevier Inc. All rights reserved.


Biomarker; Cynomolgus monkey; Dog; Guinea pig; Marmoset; Methods; Minipig; Moxifloxacin; Preclinical–clinical concordance; QT rate-correction

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk